Saxagliptin

Drug Profile

Saxagliptin

Alternative Names: BMS-477118; Onglyza; OPC-262

Latest Information Update: 11 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; Bristol-Myers Squibb; Otsuka Pharmaceutical
  • Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Dipeptides; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 03 Jul 2017 AstraZeneca plans a phase III trial for Type-2 diabetes mellitus (In children, Combination therapy) (NCT03199053)
  • 01 Aug 2016 AstraZeneca completes phase-III clinical trials in Type-2 diabetes mellitus (Combination therapy, Treatment-naive) in China (PO) (NCT02273050)
  • 05 Jul 2016 AstraZeneca plans a phase III trial for Type-2 diabetes mellitus (Combination therapy, In children, In adolescents) in United Kingdom (UKCRN31254)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top